Table 1.

Drotrecogin alfa (activated) clinical trials

Study	Study type/patients or treatments included	Number of patients included	Study period	Reference
EVAA	Dose-finding phase II	131	1997 to 1998	[10]
PROWESS	Phase III	1,690	1998 to 2000	[11]
ENHANCE	Open-label	2,378	2001 to 2003	[12]
ADDRESS	Low risk for death	2,640	2002 to 2004	[13]
RESOLVE	Sepsis in children	477	2002 to 2005	[24]
XPRESS	Heparin + DrotAA	1,927	2003 to 2005	[14]

ADDRESS, Efficacy and Safety of Drotrecogin alfa [activated] in Adult Severe Sepsis Patients at Low Risk of Death; DrotAA, drotrecogin alfa (activated); ENHANCE, Extended Evaluation of Recombinant Human Activated Protein C, drotrecogin alfa (activated); EVAA, [dose finding study]; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; RESOLVE, REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective; XPRESS, Xigris and Prophylactic Heparin Evaluation in Severe Sepsis.